Skip to main content
    A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.45
    -0.03 (-5.40%)

    Market Cap: $131.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Akebia Ther (AKBA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Akebia Ther (AKBA) trades at 0.6x sales and 6.1x book value. Its P/S of 0.6x is below its 5-year median of 1.6x. Its forward P/E is 24.6x.

    Current Multiples

    Its free cash flow yield is 11.2%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E24.6x
    Price to sales0.6x
    Price to book6.1x
    Price to FCF9.0x
    EV/FCF1.1x
    PEGN/A
    FCF yield11.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 66.7% below 1.8x and its P/B is 69.4% above 3.6x.

    MultipleCurrent5-year median10-year median
    P/S0.6x1.6x1.8x
    P/B6.1xN/A3.6x
    Medians of month-end values through Oct 2026: 52 months (5-year) and 96 to 111 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.2x in 2023 to 262.9x in 2016.

    Year endPriceP/SP/B
    2025$1.611.7x13.1x
    2024$1.902.5xN/A
    2023$1.241.2xN/A
    2022$0.58N/A20.3x
    2021$2.261.8x5.4x
    2020$2.801.3x1.6x
    2019$6.322.2x1.9x
    2018$5.531.7x1.0x
    2017$14.873.7x6.1x
    2016$10.41262.9x5.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About AKBA

    What is AKBA's forward P/E ratio?

    Akebia Ther has a forward P/E ratio of 24.6x.

    What is AKBA's price to sales ratio?

    Akebia Ther has a price to sales ratio of 0.6x.